Cargando…

Clinical significance of neoadjuvant chemotherapy for locally advanced colorectal cancer patients with deficient mismatch repair: possibly residual value in the era of immunotherapy

BACKGROUND: Deficient mismatch repair (dMMR) or microsatellite instability is one of the well-established molecular biomarkers in colorectal cancer (CRC). The efficiency of neoadjuvant chemotherapy (NAC) in locally advanced colorectal cancer (LACC) patients with dMMR is unclear. OBJECTIVES: We asses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Mian, Chen, Junguo, Huang, Jun, Liu, Huashan, Cao, Wuteng, Luo, Shuangling, Liu, Zhanzhen, Hu, Huanxin, Lai, Sicong, Hou, Yujie, Kang, Liang, Huang, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893354/ https://www.ncbi.nlm.nih.gov/pubmed/36742014 http://dx.doi.org/10.1177/17562848221150306

Ejemplares similares

Clinical significance of adjuvant chemotherapy for pathological complete response rectal cancer patients with acellular mucin pools after neoadjuvant chemoradiotherapy
por: Chen, Mian, et al.
Publicado: (2023)

Survival after curative resection for stage I colorectal mucinous adenocarcinoma
por: Huang, Liang, et al.
Publicado: (2022)

Systemic inflammatory indices predict tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer
por: Lai, Sicong, et al.
Publicado: (2020)

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
por: Wensink, G. Emerens, et al.
Publicado: (2020)

Lung cancer treatment in the era of immunotherapy
por: Xu, Yang, et al.
Publicado: (2020)

The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency
por: Yunlong, Wu, et al.
Publicado: (2022)

A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy
por: Cox, Ronald E, et al.
Publicado: (2021)

DNA mismatch repair in cancer immunotherapy
por: Guan, Junhong, et al.
Publicado: (2023)

Transanal versus Laparoscopic Total Mesorectal Excision in Male Patients with Low Tumor Location after Neoadjuvant Therapy: A Propensity Score-Matched Cohort Study
por: Li, Ze, et al.
Publicado: (2022)

The role of DNA mismatch repair in immunotherapy of human cancer
por: He, Yuchen, et al.
Publicado: (2022)

Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy
por: Yang, Zhang-Ru, et al.
Publicado: (2020)

A New MRI-Defined Biomarker for Rectal Mucinous Adenocarcinoma: Mucin Pool Patterns in Determining the Efficacy of Neoadjuvant Therapy
por: Cao, Wuteng, et al.
Publicado: (2020)

Rectal cancer restaging using 3D CUBE vs. 2D T2-weighted technique after neoadjuvant therapy: a diagnostic study
por: Cao, Wuteng, et al.
Publicado: (2017)

Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer
por: Ye, Shu-Biao, et al.
Publicado: (2020)

Radiomics-Based Preoperative Prediction of Lymph Node Status Following Neoadjuvant Therapy in Locally Advanced Rectal Cancer
por: Zhou, Xuezhi, et al.
Publicado: (2020)

CT-based deep learning model for the prediction of DNA mismatch repair deficient colorectal cancer: a diagnostic study
por: Cao, Wuteng, et al.
Publicado: (2023)

Survival outcomes analysis according to mismatch repair status in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy
por: Chen, Lin, et al.
Publicado: (2022)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era?
por: Gritti, Giuseppe, et al.
Publicado: (2017)

Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation
por: Wang, Yaqi, et al.
Publicado: (2022)

TOX as a potential target for immunotherapy in lymphocytic malignancies
por: Liang, Chaofeng, et al.
Publicado: (2021)

Value of mammographic microcalcifications and MRI-enhanced lesions in the evaluation of residual disease after neoadjuvant therapy for breast cancer
por: Zhu, Chao, et al.
Publicado: (2023)

Attention mechanism based multi-sequence MRI fusion improves prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
por: Zhou, Xuezhi, et al.
Publicado: (2023)

Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting
por: Boutin, Mélina, et al.
Publicado: (2023)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
por: Marron, Thomas U, et al.
Publicado: (2022)

Radiomics-Based Pretherapeutic Prediction of Non-response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer
por: Zhou, Xuezhi, et al.
Publicado: (2019)

Endoscopy-Based Deep Convolutional Neural Network Predicts Response to Neoadjuvant Treatment for Locally Advanced Rectal Cancer
por: Chen, Xijie, et al.
Publicado: (2022)

Management of Clinically Involved Lateral Lymph Node Metastasis in Locally Advanced Rectal Cancer: A Radiation Dose Escalation Study
por: Pang, Xiaolin, et al.
Publicado: (2021)

Lattice or Oxygen-Guided Radiotherapy: What If They Converge? Possible Future Directions in the Era of Immunotherapy
por: Ferini, Gianluca, et al.
Publicado: (2021)

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
por: Liang, Wenhua, et al.
Publicado: (2020)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
por: Li, Qing, et al.
Publicado: (2022)

Predicting pathologic complete response in locally advanced rectal cancer patients after neoadjuvant therapy: a machine learning model using XGBoost
por: Chen, Xijie, et al.
Publicado: (2022)

Safety and Feasibility of Transanal Endoscopic Surgery for Diffuse Cavernous Hemangioma of the Rectum
por: Zeng, Ziwei, et al.
Publicado: (2019)

Aspirin in the era of immunotherapy
por: Hamada, Tsuyoshi, et al.
Publicado: (2017)

Cholangiocarcinoma in the Era of Immunotherapy
por: Manthopoulou, Eleni, et al.
Publicado: (2023)

KRT17 Promotes T-lymphocyte Infiltration Through the YTHDF2–CXCL10 Axis in Colorectal Cancer
por: Liang, Wenfeng, et al.
Publicado: (2023)

Correction to: Predicting pathologic complete response in locally advanced rectal cancer patients after neoadjuvant therapy: a machine learning model using XGBoost
por: Chen, Xijie, et al.
Publicado: (2022)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)

Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis
por: Qin, Hao, et al.
Publicado: (2023)

The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy
por: Wu, Zehua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9iuam5nqf5mpja5bfap3gbak36